Do Not Switch to Cabenuva - First Achieve Viral Suppression on Biktarvy
This patient should NOT be switched to Cabenuva at this time. With a viral load of 68,000 copies/mL, the patient has virologic failure (defined as HIV RNA >200 copies/mL), and current guidelines explicitly contraindicate switching to long-acting cabotegravir/rilpivirine in this setting 1.
Why Cabenuva is Contraindicated Now
The 2025 IAS-USA guidelines are unequivocal: long-acting cabotegravir plus rilpivirine is not recommended in individuals with documented or suspected resistance to either agent 1. More critically, the FDA label for Cabenuva states it is indicated only for patients who are virologically suppressed (HIV-1 RNA <50 copies/mL) with no history of treatment failure and no known or suspected resistance to cabotegravir or rilpivirine 2.
Your patient's current virologic failure on Biktarvy (which contains the high-barrier integrase inhibitor bictegravir) raises serious concerns about:
- Potential integrase resistance that could compromise cabotegravir (also an integrase inhibitor)
- Unknown NNRTI resistance that would render rilpivirine ineffective
- Adherence patterns that make long-acting therapy particularly risky
The Correct Management Algorithm
Step 1: Resume Biktarvy Immediately with Adherence Support
Resume the current bictegravir-based regimen even before resistance testing results return, provided the patient commits to adherence 1. The guidelines specifically recommend this approach for patients who have stopped integrase-based regimens, as many will achieve viral suppression if adherence improves 1.
Step 2: Obtain Resistance Testing
Order genotypic resistance testing immediately while the patient is on therapy. This is essential to:
- Rule out integrase resistance (which would affect both current and future options)
- Identify any NNRTI resistance (critical for future Cabenuva consideration)
- Guide definitive treatment decisions
Step 3: Intensive Adherence Counseling
The patient's promise of "strict adherence in future" requires concrete intervention:
- Identify specific barriers to adherence (stigma, pill burden, side effects, mental health, substance use)
- Implement adherence support strategies (pill boxes, reminders, directly observed therapy if needed)
- Consider case management referral 1
Step 4: Reassess After Achieving Viral Suppression
Only after achieving and maintaining HIV RNA <50 copies/mL for at least 6 months should Cabenuva be reconsidered, and only if:
- Resistance testing confirms full susceptibility to both cabotegravir AND rilpivirine
- The patient has demonstrated consistent adherence on oral therapy
- No hepatitis B coinfection is present 1
The Exception That Doesn't Apply Here
The guidelines do describe one narrow scenario where Cabenuva might be used in viremic patients: those with advanced HIV disease (CD4 <200 or AIDS-defining illness) who are unable to take oral ART consistently despite extensive efforts and have virus susceptible to both agents 1. However, this requires:
- Documented inability to take oral medications despite intensive support
- High risk of disease progression
- Confirmed susceptibility to both drugs
- Intensive case management
Your patient doesn't meet these criteria - they simply missed doses but state they will adhere in the future, which is exactly the scenario where oral therapy should be optimized first.
Critical Pitfall to Avoid
Do not be swayed by the patient's preference for injections or promises of future adherence. The guidelines explicitly warn that switching to regimens with lower barriers to resistance (rilpivirine is an NNRTI with low barrier) in the setting of virologic failure and potential adherence issues carries high risk of resistance development 1. Once resistance to cabotegravir or rilpivirine develops, this valuable long-acting option is permanently lost.
Bottom Line
Achieve viral suppression on Biktarvy first, confirm susceptibility through resistance testing, demonstrate sustained adherence for at least 6 months, then reassess Cabenuva eligibility. The patient's current virologic failure is an absolute contraindication to switching to long-acting therapy 1, 2.